Equities

Genovis AB

Genovis AB

Actions
  • Price (SEK)26.80
  • Today's Change0.05 / 0.19%
  • Shares traded93.92k
  • 1 Year change-43.28%
  • Beta1.7008
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

  • Revenue in SEK (TTM)127.02m
  • Net income in SEK17.25m
  • Incorporated1999
  • Employees37.00
  • Location
    Genovis ABMedicon Village, Scheelevagen 2LUND 223 63SwedenSWE
  • Phone+46 46101230
  • Fax+46 46128020
  • Websitehttps://www.genovis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
C Rad AB497.02m53.43m937.77m94.0018.013.1814.981.891.581.5814.728.961.235.042.725,712,816.0013.255.0919.167.0246.3043.1210.814.862.32--0.00490.0040.9217.44375.0510.8933.69--
Optomed Oyj169.98m-56.07m972.00m110.00--3.07--5.72-0.2761-0.27610.85011.400.47621.694.10129,035.10-15.71-12.95-19.11-15.9067.7765.69-32.98-27.842.67--0.1424--3.003.4718.84--7.26--
Bactiguard Holding AB254.96m-56.11m1.13bn163.00--3.88--4.43-1.60-1.607.289.370.37063.847.601,174,917.00-8.16-7.56-11.32-8.8147.5347.91-22.01-26.280.5898-2.720.4175---11.966.46-161.71--8.43--
BioPorto A/S52.41m-77.48m1.17bn33.00--7.18--22.25-0.1397-0.13970.09410.2440.27773.239.021,091,290.00-41.06-71.10-51.28-96.5571.1363.38-147.84-239.225.16--0.0517--6.873.5425.81---51.56--
Sedana Medical AB (publ)174.14m-57.24m1.28bn78.00--1.34--7.34-0.5763-0.57631.759.560.16971.1610.142,204,317.00-5.58-5.77-5.84-6.0870.6064.06-32.87-36.136.02-30.480.0076--25.2321.5918.90--42.12--
Paxman AB (publ)238.86m28.64m1.35bn102.0047.239.2628.765.651.501.5012.547.671.312.746.562,624,791.0015.66-5.0820.74-7.7670.2769.3811.99-5.071.9812.730.0838--43.9929.35180.69--6.26--
Nordhealth As477.01m-107.78m1.64bn355.00--3.1797.363.43-1.41-1.416.2011.640.4329--6.731,228,757.00-9.78---11.11--85.82---22.59------0.00--18.60--21.96------
Genovis AB127.02m17.25m1.75bn37.00101.528.4360.2513.790.26350.26351.943.170.4938----3,432,973.006.7118.567.2121.4564.4165.5113.5823.88--697.000.27180.0054.5435.56449.56--47.59--
Stille AB487.43m50.86m1.91bn151.0033.662.8525.513.936.336.3360.9474.850.69782.108.494,598,368.007.287.038.708.1949.1743.9310.439.851.127.410.0021.9819.7016.78-2.485.3423.62--
Detection Technology Oyj-1.16tn-1.16tn2.35bn464.00--2.76----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
Medistim ASA537.67m99.89m2.49bn152.0024.876.2419.984.635.555.5529.8722.121.130.74617.483,599,204.0021.0522.9325.5328.5279.1278.2518.5820.642.75--0.018175.257.0010.06-8.9112.720.03314.87
BICO Group AB2.25bn-786.80m2.62bn828.00--0.9085--1.16-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Data as of Nov 12 2024. Currency figures normalised to Genovis AB's reporting currency: Swedish Krona SEK

Institutional shareholders

36.50%Per cent of shares held by top holders
HolderShares% Held
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 29 Sep 20234.67m7.13%
�landsbanken Abp (Private Banking)as of 28 Jun 20243.65m5.58%
Teknik Innovation Norden Fonder ABas of 28 Jun 20243.32m5.07%
Swedbank Robur Fonder ABas of 30 Sep 20243.10m4.74%
Andra AP-fondenas of 28 Jun 20242.23m3.41%
Aktia Bank Plc (Investment Management)as of 30 Sep 20241.97m3.01%
Danske Bank A/S (Investment Management)as of 31 Oct 20241.92m2.93%
Case Kapitalf�rvaltning ABas of 31 Aug 20241.69m2.59%
Lonvia Capital SASUas of 30 Jun 2024711.05k1.09%
Danske Bank A/S (Investment Management Sweden)as of 30 Jun 2024629.30k0.96%
More ▼
Data from 31 Dec 2022 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.